Elanco Q1 2025 Earnings Report
Key Takeaways
Elanco Animal Health reported first quarter 2025 revenue of $1,193 million, a 1% decrease year-over-year but a 4% increase in organic constant currency. The company reported net income of $67 million and adjusted net income of $184 million. Reported EPS was $0.13 and adjusted EPS was $0.37. The company raised its full-year 2025 revenue guidance.
First quarter 2025 revenue was $1,193 million, a 1% decrease year-over-year but a 4% increase in organic constant currency.
Reported Net Income was $67 million, and Adjusted Net Income was $184 million.
Reported EPS was $0.13, and Adjusted EPS was $0.37.
Elanco is raising full-year 2025 revenue guidance to $4,510 to $4,580 million.
Elanco
Elanco
Elanco Revenue by Segment
Forward Guidance
Elanco is raising its full year 2025 revenue guidance to $4,510 to $4,580 million and maintaining adjusted EBITDA and adjusted EPS guidance.
Positive Outlook
- Raising 2025 revenue guidance driven by foreign exchange tailwind and strong first quarter performance.
- Increasing 2025 innovation revenue target to $660 to $740 million.
- Expecting accelerating organic constant currency revenue growth to mid-single digits.
- Expecting gross debt paydown of $450 to $500 million in 2025.
- 2025 year-end net leverage ratio target improved to 3.9x to 4.3x.
Challenges Ahead
- Reported Net Loss of $(35) to $(7) million expected for the full year.
- Reported Loss Per Share of $(0.07) to $(0.01) expected for the full year.
- Outlook incorporates current estimate for tariff net impact of $16 to $20 million to Adjusted EBITDA.
- Expected continued macro volatility factored into outlook.
- Second quarter guidance anticipates approximately $5 million headwind to revenue from unfavorable foreign exchange rates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income